Resetting the Evidence Bar for New Anticancer Drug Approvals - Top-Institutions - MDSpire

Resetting the Evidence Bar for New Anticancer Drug Approvals

  • By

  • Stacie B. Dusetzina

  • Shelley A. Jazowski

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Oncology

  • #2

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, MD

    Key Differentiators

    • Oncology

  • #3

    American Society of Clinical Oncology
    American Society of Clinical Oncology

    Alexandria, VA

    Key Differentiators

    • Oncology

  • #4

    National Institutes of Health
    National Institutes of Health

    Bethesda, MD

    Key Differentiators

    • Oncology

Original Source(s)

Resetting the Evidence Bar for New Anticancer Drug Approvals

  • by Stacie B. Dusetzina, Shelley A. Jazowski

  • June 9, 2026

Related Content

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

Editorial: New Insights on Sialic Acid and Sialylated Glycans in the Tumorigenic Process

Impact of body mass index on dietary habits and health behaviors in breast cancer patients